Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD43 Double Nickase Plasmid (h): sc-402688-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD43 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD43 Double Nickase Plasmid (h) and CD43 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting SPN. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD43 Antibody (DF-T1): sc-6256
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD43 Double Nickase Plasmid (h) | sc-402688-NIC | 20 µg | $410.00 | |||
CD43 Double Nickase Plasmid (h2) | sc-402688-NIC-2 | 20 µg | $410.00 |
SPN encodes CD43 (leukosialin), a heavily O-glycosylated sialomucin expressed on most hematopoietic cells that regulates leukocyte adhesion, migration, and activation. CD43 modulates immune synapse architecture and cell–cell interactions by influencing integrin-dependent adhesion, cytoskeletal dynamics, and signaling downstream of antigen receptors in T cells and B cells. Through its effects on trafficking and activation thresholds, CD43 contributes to inflammatory responses and immune homeostasis across myeloid and lymphoid lineages. Altered CD43 expression or glycoform composition is frequently evaluated in immune dysregulation and hematologic malignancy research as a marker linked to differentiation state and aberrant signaling.
CD43 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the SPN locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within SPN. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt SPN function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of SPN-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.